Radioimmunoguided surgery in recurrent colorectal cancer: the role of carcinoembryonic antigen, computerized tomography, and physical examination
- PMID: 2799440
Radioimmunoguided surgery in recurrent colorectal cancer: the role of carcinoembryonic antigen, computerized tomography, and physical examination
Abstract
From January 1986 to December 1987, 32 patients with recurrent colorectal cancer had second-look radioimmunoguided surgery (RIGS system). All patients had pathologic confirmation of recurrence. The RIGS system identified 81% of recurrences, and in six patients recurrent tumor was identified only by RIGS. All patients had physical examination, carcinoembryonic antigen (CEA) assay, and computerized tomography of the abdomen and pelvis. Detection of recurrence was based on symptoms in six, elevated CEA value in 25, and physical examination in one. The CEA was elevated preoperatively in 30 patients; two false-negative results occurred in symptomatic patients who had pelvic recurrence. The median CEA value in those with liver recurrence was 30 ng/ml (range 5.2 to 298) and for pelvic recurrence 13 ng/ml (range 1.9 to 31) (P less than .05). The overall sensitivity of CT was 41% (abdomen other than liver 37%, liver 56%, and pelvis 22%). The combination of elevated CEA, symptoms, and physical findings identified 100% of recurrences. We conclude that a rising CEA remains the most accurate indicator of recurrence. CT should not be done routinely to detect recurrent colorectal cancer unless CEA is elevated or the patient is symptomatic. In our study the intraoperative use of the RIGS system aided the surgeon in identifying occult tumors.
Similar articles
-
Role of B72.3 iodine 125-labeled monoclonal antibody in colorectal cancer detection by radioimmunoguided surgery.Surgery. 1994 Feb;115(2):190-8. Surgery. 1994. PMID: 8310407
-
A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer.Colorectal Dis. 2007 Jul;9(6):527-31. doi: 10.1111/j.1463-1318.2007.01176.x. Colorectal Dis. 2007. PMID: 17573747
-
CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.Anticancer Res. 1999 Jul-Aug;19(4A):2443-50. Anticancer Res. 1999. PMID: 10470173
-
CEA monitoring in colorectal cancer. What you should know.Oncology (Williston Park). 2006 May;20(6):579-87; discussion 588, 594, 596 passim. Oncology (Williston Park). 2006. PMID: 16773844 Review.
-
[Diagnosis and therapy of metastatic and recurrent colorectal tumors].Orv Hetil. 1990 Mar 18;131(11):559-62. Orv Hetil. 1990. PMID: 1690376 Review. Hungarian.
Cited by
-
Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.Mol Pharm. 2009 Mar-Apr;6(2):428-40. doi: 10.1021/mp9000052. Mol Pharm. 2009. PMID: 19718796 Free PMC article.
-
Follow-up plans after treatment of primary colon and rectum cancer.World J Surg. 1991 Sep-Oct;15(5):583-8. doi: 10.1007/BF01789202. World J Surg. 1991. PMID: 1949855 Review.
-
Blood CEA levels for detecting recurrent colorectal cancer.Cochrane Database Syst Rev. 2015 Dec 10;2015(12):CD011134. doi: 10.1002/14651858.CD011134.pub2. Cochrane Database Syst Rev. 2015. PMID: 26661580 Free PMC article.
-
A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma.Tumour Biol. 2016 Feb;37(2):2539-46. doi: 10.1007/s13277-015-4025-7. Epub 2015 Sep 19. Tumour Biol. 2016. PMID: 26386723
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical